Effects of MAP kinase cascade inhibitors on the MKK5/ERK5 pathway

Nimesh Mody, J Leitch, C Armstrong, J Dixon, P Cohen

Research output: Contribution to journalArticle

213 Citations (Scopus)

Abstract

Antibodies that recognise the active phosphorylated forms of mitogen-activated protein kinase (MAPK) kinase 5 (MKK5) and extracellular signal-regulated kinase 5 (ERK5) in untransfected cells have been exploited to show that the epidermal growth factor (EGF)-induced activation of MKK5 and ERK5 occurs subsequent to the activation of ERK1 and ERK2 in HeLa cells. The drugs U0126 and PD184352, which prevent the activation of MKK1 (and hence the activation of ERK1/ERK2), also prevent the activation of MKK5, although higher concentrations are required. Our studies define physiological targets of the MKK5/ERK5 pathway as proteins whose phosphorylation is largely prevented by 10 microM PD184352, but unaffected by 2 microM PD184352. Surprisingly, 2 microM PD184352 prolongs the activation of MKK5 and ERK5 induced by EGF or H(2)O(2), indicating negative control of the MKK5/ERK5 pathway by the classical MAPK cascade. Our results also indicate that ERK5 is not a significant activator of MAPK-activated protein kinase-1/RSK in HeLa cells.
Original languageEnglish
Pages (from-to)21-24
Number of pages4
JournalFEBS Letters
Volume502
Issue number1-2
Early online date4 Jul 2001
Publication statusPublished - 27 Jul 2001

Fingerprint

Mitogen-Activated Protein Kinase 7
MAP Kinase Signaling System
Mitogen-Activated Protein Kinase Kinases
Phosphotransferases
Chemical activation
Mitogen-Activated Protein Kinases
HeLa Cells
MAP Kinase Kinase 5
Epidermal Growth Factor
Phosphorylation
Protein Kinases
2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide
Antibodies

Keywords

  • Amino Acid Sequence
  • Animals
  • Benzamides
  • Butadienes
  • Enzyme Activation
  • Enzyme Inhibitors
  • Flavonoids
  • Hela Cells
  • Humans
  • MAP Kinase Signaling System
  • Mitogen-Activated Protein Kinase 7
  • Mitogen-Activated Protein Kinase Kinases
  • Mitogen-Activated Protein Kinases
  • Molecular Sequence Data
  • Nitriles
  • Phosphorylation
  • Sheep
  • Mitogen-activated protein kinase
  • Mitogen-activated protein kinase kinase 5
  • Extracellular signal-regulated kinase 5
  • BMK1
  • PD184352

Cite this

Mody, N., Leitch, J., Armstrong, C., Dixon, J., & Cohen, P. (2001). Effects of MAP kinase cascade inhibitors on the MKK5/ERK5 pathway. FEBS Letters, 502(1-2), 21-24.

Effects of MAP kinase cascade inhibitors on the MKK5/ERK5 pathway. / Mody, Nimesh; Leitch, J; Armstrong, C; Dixon, J; Cohen, P.

In: FEBS Letters, Vol. 502, No. 1-2, 27.07.2001, p. 21-24.

Research output: Contribution to journalArticle

Mody, N, Leitch, J, Armstrong, C, Dixon, J & Cohen, P 2001, 'Effects of MAP kinase cascade inhibitors on the MKK5/ERK5 pathway', FEBS Letters, vol. 502, no. 1-2, pp. 21-24.
Mody N, Leitch J, Armstrong C, Dixon J, Cohen P. Effects of MAP kinase cascade inhibitors on the MKK5/ERK5 pathway. FEBS Letters. 2001 Jul 27;502(1-2):21-24.
Mody, Nimesh ; Leitch, J ; Armstrong, C ; Dixon, J ; Cohen, P. / Effects of MAP kinase cascade inhibitors on the MKK5/ERK5 pathway. In: FEBS Letters. 2001 ; Vol. 502, No. 1-2. pp. 21-24.
@article{ca92128958b046a9bd4838c7f6c68d6d,
title = "Effects of MAP kinase cascade inhibitors on the MKK5/ERK5 pathway",
abstract = "Antibodies that recognise the active phosphorylated forms of mitogen-activated protein kinase (MAPK) kinase 5 (MKK5) and extracellular signal-regulated kinase 5 (ERK5) in untransfected cells have been exploited to show that the epidermal growth factor (EGF)-induced activation of MKK5 and ERK5 occurs subsequent to the activation of ERK1 and ERK2 in HeLa cells. The drugs U0126 and PD184352, which prevent the activation of MKK1 (and hence the activation of ERK1/ERK2), also prevent the activation of MKK5, although higher concentrations are required. Our studies define physiological targets of the MKK5/ERK5 pathway as proteins whose phosphorylation is largely prevented by 10 microM PD184352, but unaffected by 2 microM PD184352. Surprisingly, 2 microM PD184352 prolongs the activation of MKK5 and ERK5 induced by EGF or H(2)O(2), indicating negative control of the MKK5/ERK5 pathway by the classical MAPK cascade. Our results also indicate that ERK5 is not a significant activator of MAPK-activated protein kinase-1/RSK in HeLa cells.",
keywords = "Amino Acid Sequence, Animals, Benzamides, Butadienes, Enzyme Activation, Enzyme Inhibitors, Flavonoids, Hela Cells, Humans, MAP Kinase Signaling System, Mitogen-Activated Protein Kinase 7, Mitogen-Activated Protein Kinase Kinases, Mitogen-Activated Protein Kinases, Molecular Sequence Data, Nitriles, Phosphorylation, Sheep, Mitogen-activated protein kinase, Mitogen-activated protein kinase kinase 5, Extracellular signal-regulated kinase 5, BMK1, PD184352",
author = "Nimesh Mody and J Leitch and C Armstrong and J Dixon and P Cohen",
year = "2001",
month = "7",
day = "27",
language = "English",
volume = "502",
pages = "21--24",
journal = "FEBS Letters",
issn = "0014-5793",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Effects of MAP kinase cascade inhibitors on the MKK5/ERK5 pathway

AU - Mody, Nimesh

AU - Leitch, J

AU - Armstrong, C

AU - Dixon, J

AU - Cohen, P

PY - 2001/7/27

Y1 - 2001/7/27

N2 - Antibodies that recognise the active phosphorylated forms of mitogen-activated protein kinase (MAPK) kinase 5 (MKK5) and extracellular signal-regulated kinase 5 (ERK5) in untransfected cells have been exploited to show that the epidermal growth factor (EGF)-induced activation of MKK5 and ERK5 occurs subsequent to the activation of ERK1 and ERK2 in HeLa cells. The drugs U0126 and PD184352, which prevent the activation of MKK1 (and hence the activation of ERK1/ERK2), also prevent the activation of MKK5, although higher concentrations are required. Our studies define physiological targets of the MKK5/ERK5 pathway as proteins whose phosphorylation is largely prevented by 10 microM PD184352, but unaffected by 2 microM PD184352. Surprisingly, 2 microM PD184352 prolongs the activation of MKK5 and ERK5 induced by EGF or H(2)O(2), indicating negative control of the MKK5/ERK5 pathway by the classical MAPK cascade. Our results also indicate that ERK5 is not a significant activator of MAPK-activated protein kinase-1/RSK in HeLa cells.

AB - Antibodies that recognise the active phosphorylated forms of mitogen-activated protein kinase (MAPK) kinase 5 (MKK5) and extracellular signal-regulated kinase 5 (ERK5) in untransfected cells have been exploited to show that the epidermal growth factor (EGF)-induced activation of MKK5 and ERK5 occurs subsequent to the activation of ERK1 and ERK2 in HeLa cells. The drugs U0126 and PD184352, which prevent the activation of MKK1 (and hence the activation of ERK1/ERK2), also prevent the activation of MKK5, although higher concentrations are required. Our studies define physiological targets of the MKK5/ERK5 pathway as proteins whose phosphorylation is largely prevented by 10 microM PD184352, but unaffected by 2 microM PD184352. Surprisingly, 2 microM PD184352 prolongs the activation of MKK5 and ERK5 induced by EGF or H(2)O(2), indicating negative control of the MKK5/ERK5 pathway by the classical MAPK cascade. Our results also indicate that ERK5 is not a significant activator of MAPK-activated protein kinase-1/RSK in HeLa cells.

KW - Amino Acid Sequence

KW - Animals

KW - Benzamides

KW - Butadienes

KW - Enzyme Activation

KW - Enzyme Inhibitors

KW - Flavonoids

KW - Hela Cells

KW - Humans

KW - MAP Kinase Signaling System

KW - Mitogen-Activated Protein Kinase 7

KW - Mitogen-Activated Protein Kinase Kinases

KW - Mitogen-Activated Protein Kinases

KW - Molecular Sequence Data

KW - Nitriles

KW - Phosphorylation

KW - Sheep

KW - Mitogen-activated protein kinase

KW - Mitogen-activated protein kinase kinase 5

KW - Extracellular signal-regulated kinase 5

KW - BMK1

KW - PD184352

M3 - Article

VL - 502

SP - 21

EP - 24

JO - FEBS Letters

JF - FEBS Letters

SN - 0014-5793

IS - 1-2

ER -